Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rated Buy in New Coverage at HC Wainwright

Posted by Francis Steltz on Nov 2nd, 2026

Research analysts at HC Wainwright started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) in a research report issued to clients and investors on Monday, Briefing.com reports. The brokerage set a “buy” rating and a $52.00 price target on the stock. HC Wainwright‘s price objective suggests a potential upside of 23.60% from the stock’s current price.

Several other research firms have also weighed in on TEVA. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Barclays boosted their target price on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a report on Thursday, October 15th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Oppenheimer raised their price target on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, October 9th. Finally, TD Cowen began coverage on Teva Pharmaceutical Industries in a research report on Thursday, October 1st. They issued a “buy” rating and a $55.00 price objective for the company. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.54.

View Our Latest Research Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $42.07 on Monday. The firm has a market cap of $49.02 billion, a PE ratio of 70.12, a price-to-earnings-growth ratio of 3.90 and a beta of 0.89. Teva Pharmaceutical Industries has a 12 month low of $19.98 and a 12 month high of $42.59. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. The company’s 50-day moving average price is $39.07 and its two-hundred day moving average price is $34.55.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the transaction, the insider owned 8,500 shares in the company, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 374,959 shares of company stock valued at $14,644,285. Insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 2.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock valued at $1,384,216,000 after buying an additional 1,004,941 shares during the period. WCM Investment Management LLC boosted its holdings in Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after buying an additional 26,813,522 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Teva Pharmaceutical Industries by 5.8% during the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock worth $259,899,000 after buying an additional 419,329 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Teva Pharmaceutical Industries by 1.5% during the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock worth $145,076,000 after buying an additional 72,880 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in shares of Teva Pharmaceutical Industries by 1.6% during the 1st quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock worth $131,036,000 after buying an additional 70,058 shares during the period. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.